Quality Improvement Tools for Opioid Use Disorder
(PROMOTE-QI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial seeks to find better ways to keep people in opioid treatment programs (OTPs) longer, potentially leading to improved recovery outcomes. It compares three groups: one using a quality improvement (QI) toolkit, another using the QI toolkit with additional support from external QI facilitators, and a third receiving regular care. Participants come exclusively from BayMark OTPs, focusing on existing clinics. The study will measure how long patients remain in treatment and examine other health impacts, such as hospital visits and overdoses. The goal is to identify strategies that can help clinics effectively improve patient retention.
As an unphased trial, this study provides an opportunity to contribute to research that could enhance treatment strategies and improve patient outcomes.
Do I need to stop my current medications to join the trial?
The trial focuses on improving retention in opioid treatment programs and does not specify if participants need to stop their current medications. It seems likely that staying on methadone or buprenorphine is encouraged, as the study aims to keep patients in care.
What prior data suggests that these quality improvement tools are safe for opioid treatment programs?
Research has shown that the Quality Improvement (QI) Toolkit and External QI Facilitation used in this study are generally safe and well-tolerated. The QI Toolkit aids clinics in enhancing care for patients with opioid use disorder by organizing tasks and providing useful tools. No safety concerns have been reported from using the toolkit, as it focuses on improving clinic practices rather than directly treating patients.
Similarly, External QI Facilitation supports clinics in making improvements with the help of facilitators. This involves coaching teams to implement changes that enhance patient care. This method has been used in other healthcare settings without any reported harm. It focuses on supporting staff rather than directly affecting patients, posing minimal risk. Overall, both tools aim to improve clinic operations and keep patients in treatment, making them safe options for participating clinics.12345Why are researchers excited about this trial?
Researchers are excited about these quality improvement tools for opioid use disorder because they offer innovative strategies to enhance treatment retention compared to traditional methods. Unlike usual care, which often lacks structured guidance, the QI toolkit provides clinics with evidence-based resources and templates to drive meaningful change. Additionally, the external QI facilitation arm introduces expert coaching through structured frameworks like the NIATx model, aiming to guide clinics in implementing effective retention strategies. This hands-on support and data-driven feedback could significantly improve patient outcomes by fostering a more responsive and adaptive treatment environment.
What evidence suggests that this trial's quality improvement tools could be effective for opioid use disorder?
Research has shown that quality improvement (QI) toolkits can enhance opioid treatment programs by helping retain patients. In one study, 76% of participants reported that their QI project improved their management of opioid treatment. Participants in this trial may receive a QI toolkit to monitor each step of treatment, potentially improving the program's overall performance and saving lives.
For clinics in this trial using external QI facilitation, evidence indicates that structured guidance can further improve patient retention. This method includes coaching and regular data reviews to implement effective changes. Overall, these strategies offer practical ways to keep patients in care longer, which is crucial for successful treatment.16789Who Is on the Research Team?
Tami L Mark, PhD
Principal Investigator
RTI International
Are You a Good Fit for This Trial?
This trial is for BayMark opioid treatment programs (OTPs) looking to improve patient retention. It aims to help patients stay on methadone or buprenorphine, which leads to better outcomes. Only BayMark OTPs can participate; there are no specific exclusion criteria mentioned.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Implementation
OTPs are provided with quality measures and a QI toolkit, with or without external facilitation, to improve patient retention
Follow-up
Participants are monitored for retention and secondary outcomes such as ED visits and hospitalizations
What Are the Treatments Tested in This Trial?
Interventions
- External QI Facilitation
- Quality Improvement (QI) Toolkit
- Quality Measures (Audit and Feedback)
Find a Clinic Near You
Who Is Running the Clinical Trial?
RTI International
Lead Sponsor
University of California, Los Angeles
Collaborator
BayMark Health Services
Collaborator
Los Angeles County Department of Public Health - Substance Abuse Prevention and Control (SAPC)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator